Scaling Healthcare Innovation: Life Sciences, MedTech and HealthTech Success Stories from the Goldman Sachs 10,000 Small Businesses UK Programme #10KSBUK

Nelson Advisors
7 minutes ago
12 min read

The persistent productivity puzzle within the United Kingdom remains a major structural challenge for economists, academic institutions, and policymakers. While the British economy excels at spawning startups, transition rates from early-stage micro-enterprises to scaling, mid-market companies have historically been constrained by a pronounced management and leadership support gap. This barrier is particularly challenging in highly technical, regulated, and capital-intensive sectors such as life sciences, biotechnology, medtech, and healthtech, where long research and development cycles, complex clinical validation pathways, and talent acquisition hurdles compound the difficulties of scaling.

To bridge this critical growth deficit, the Goldman Sachs 10,000 Small Businesses (10KSB) UK programme has acted as a vital educational and strategic intervention since its launch in 2010. Fully funded by the Goldman Sachs Foundation, the initiative provides high-growth small business leaders and social entrepreneurs with 100 hours of practical business and management education. Developed by leading experts, the curriculum is delivered in partnership with top-tier academic institutions, including Saïd Business School at the University of Oxford, the Aston Centre for Growth at Aston University, Leeds University Business School at the University of Leeds, and the Manchester Metropolitan University Business School.

By targeting decision-makers of companies operating for at least three years with 5 to 50 employees and annual revenues exceeding £250,000, the programme provides the structural tools necessary to design and execute a robust, customized Business Growth Plan. An analysis of health-related business success stories within this framework shows how targeted business education helps scientific and clinical founders scale their companies, navigate market challenges, and create high-value employment.

Longitudinal Economic Impact and the 10KSB Programme Effect

The macroeconomic contribution of the 10KSB UK programme has expanded considerably over its fifteen-year history. Evaluations conducted by the Enterprise Research Centre (ERC) demonstrate that programme graduates achieve significantly higher rates of job creation, revenue generation, and productivity growth compared to matched control groups of similar size, age, and sector.

The growth trajectory of the programme's aggregate economic footprint is detailed in the table below:

Longitudinal Milestones (Year of Report)	Total Scaling Graduates	Combined Annual Revenue	Estimated Combined Headcount	Key Operational & Strategic Indicators
Early Evaluation Phase (2015)	2,300+ (US & UK combined sites)	N/A (Initial US/UK baseline collection)	N/A (Baseline operational metrics)	66.8% of graduates reported revenue growth within 6 months; 76.0% grew revenues within 18 months.
Middle Scaling Phase (2022)	1,900+ (UK graduates)	£2.8 billion	N/A (Focus on pandemic retention)	63% invested in R&D during the pandemic; 62% planned continued R&D investment over 2 years.
Advanced Scaling Phase (2024)	2,300+ (UK graduates)	£5.9 billion	53,000+ employees	47% expanded workforce during macro headwinds; 26% recorded annual turnover growth above 20%.
15-Year Milestone (2025)	2,500+ (UK graduates)	£10.6 billion	82,000+ employees	Combined 15-year net addition of £2.7 billion in revenue and 41,313 jobs directly attributable to the programme.

This expansion is supported by deep behavioural changes. Following graduation, 94% of participants report higher confidence in managing scaling challenges, 84% systematically utilise financial data to drive strategic decisions, 97% feel more effective as business leaders, and 90% introduce new corporate processes or organisational systems.

According to the Enterprise Research Centre, three years after completing the programme, 10KSB UK graduates outperform similar companies by increasing revenues by up to 43% more and growing their staff by over a third. The programme's impact also includes a 14% outperformance in productivity compared to equivalent companies, directly addressing the UK's broader productivity challenges.

Pandemic Adaptation and Resilience Strategies

The structural resilience of 10KSB UK alumni was tested during the COVID-19 pandemic. While SMEs generally faced severe disruptions, 10KSB graduates pivoted quickly by using the strategic frameworks of their business education.

To support its network, the 10KSB UK programme launched the "Reimagining Business" initiative between March and May 2020, delivering targeted webinars, weekly coaching sessions, and faculty insights to over 450 small business leaders.

This continuous support helped guide major pivots. Approximately 80% of programme participants revised their pre-pandemic business models, 68% adapted their operational structures, 69% successfully launched new products or services, and 88% accelerated their adoption of digital technologies.

Within health-related sectors, many women-run and founder-led businesses exposed to healthcare, technology, or remote-capable operations reported revenue increases during the pandemic by adapting to meet shifting clinical and clinical-support needs.

Sectoral Success Stories in the Life Sciences, Medtech and Healthtech

The practical application of the 10KSB curriculum is best demonstrated through the growth of specific companies in the life sciences, medtech, and healthtech fields. These firms have successfully converted business training into scalable clinical and commercial operations.

CatSci: Transitioning from Catalyst Screening to Global Drug Development

CatSci Ltd, based in Cardiff, Wales, is a prominent life sciences success story that illustrates the journey from a specialised laboratory service to a globally recognised pharmaceutical innovation partner. Founded in 2011 by scientists following a spin-out from AstraZeneca, the business was initially established as a catalyst screening company.

By 2019, CatSci operated with a turnover of £3 Million and employed 25 people. To scale further, Chief Executive Officer Dr. Ross Burn completed the 10KSB UK programme at Oxford Saïd Business School to build the commercial systems needed to expand the firm's global presence.

Through the programme, Burn refined CatSci’s strategy and transitioned the company's focus to the broader, high-value field of process research and development for new medicines, with a particular focus on the development of scalable oligonucleotide therapeutics to support emerging RNA-based pipelines. This repositioning helped the firm grow past its initial targets.

Between 2018 and 2022, CatSci grew its revenues by an average of 50% annually, expanded its headcount to 76, and grew its international trade footprint across 13 countries—including entry into the Japanese, European, and US markets. This growth in international trade earned CatSci the Queen’s Award for Enterprise in International Trade in 2022.

By building solid financial and operational structures, CatSci successfully positioned itself to secure a major institutional investment from European private equity firm Keensight Capital, helping fund its continued laboratory expansion.

https://catsci.com/about-us/our-history/

June Medical: Scaling Medtech Manufacturing through Operational Excellence

June Medical, an award-winning medical device manufacturer founded by Angela Spång, shows how medtech scale-ups can use process innovation and structured workforce development to capture international market share. June Medical is best known for developing and manufacturing single-use, plastic injection molded surgical retraction systems made of advanced Terlux polymers, which improve surgical access and sterile control in urological procedures.

Spång enrolled in the 10KSB UK programme, a curriculum she compared to a condensed Executive MBA, to build the management capacity required to scale her proprietary medical products globally. The programme challenged her to redefine her company's value proposition and transition from a localised distributor to an international IP-led manufacturer.

This strategic development culminated in June Medical being named the "Most Innovative Business" winner across the entire 10KSB UK alumni community during the programme's 15th-anniversary milestone celebration at the Tate Modern in 2025.

To support this rapid product growth, June Medical addressed the technical skills shortage in manufacturing by implementing a structured apprenticeship scheme. By standardising its training and operational processes, the company successfully integrated young apprentices into its commercial workflows, helping expand operations at its UK facilities and launch its US-focused export pipelines.

https://junemedical.com

Principle Healthcare: Internationalising Nutraceutical Manufacturing

Principle Healthcare Group, based in Skipton, North Yorkshire, highlights how life sciences and consumer-health manufacturers can utilise regional business support to scale across Europe. Principle Healthcare is a major producer of vitamins, minerals and dietary supplements, with capabilities spanning formulation, advanced packaging, and large-scale manufacturing.

Through its engagement with Leeds University Business School, one of the key 10KSB UK delivery partners, the firm integrated advanced marketing, supply-chain logistics, and export strategies into its core operations.

These improvements allowed Principle Healthcare to expand its international trade footprint, leading to the company winning the UKTI Export Achievement Award at the Medilink Yorkshire and Humber Awards. The Medilink Awards celebrate the commercial achievements of healthcare technology and life sciences organisations in the region.

By building structured commercial partnerships, Principle Healthcare scaled its international brand presence and secured a market-leading position. This successful trajectory made it an attractive strategic partner, culminating in its acquisition by the global healthcare group, helping cement its position in the European nutraceutical sector.

https://www.principlehealthcare.com

Concierge Medical: Systematising Rural Private Healthcare Delivery

Concierge Medical, founded in 2013, operates a private, home-visiting general practice that provides continuous primary care across the Cotswolds and surrounding rural areas. The business model addresses a geographical challenge where access to traditional, physical primary care facilities can be difficult.

Kat Carrick, representing Concierge Medical, completed the 10KSB UK curriculum to address operational constraints that were bottlenecking the company's growth. The clinical founders needed structured management frameworks to transition from a localised, hands-on medical practice into a scalable, membership-based healthcare business.

The programme provided the tools necessary to analyse and resolve operational inefficiencies, leading to the design of a standardised, technology-enabled primary care platform. Following graduation, Concierge Medical recorded a 98% increase in its subscription membership base within six months.

The confidence and operational discipline gained during the course helped the leadership set more ambitious growth targets, prompting the company to actively seek institutional external investment to scale its rural concierge model to other underserved regions across the UK.

https://www.conciergemedical.co.uk/about-us/

Myonex: Rebranding and Scaling Global Clinical Trial Supply Channels

Myonex, formerly known as Myoderm, shows how clinical trial support services can pivot their brand and operational footprint to capture global pharmaceutical demand. While the company had built a strong reputation in clinical trial supply within the United States, it initially struggled to scale its brand internationally.

A major barrier was a widespread misconception among global audiences that the suffix "-derm" in the company's original name limited its services to dermatology clinical trials.

To support its global expansion and clear up this market misconception, the company underwent a comprehensive rebranding process, officially launching as Myonex in 2020. This rebrand was supported by extensive market research, including interviews and surveys with life sciences professionals across Europe and North America.

The strategic shift helped accelerate growth, with Myonex recording annual growth rates exceeding 20% for three consecutive years. During this scaling phase, the company tripled its global headcount, introduced new services tailored for decentralised clinical trials, opened a new 65,000-square-foot global headquarters in the US, and significantly expanded the clinical supply capacity of its UK-based facilities.

https://www.myonex.com/

Ada Jabaru and Nistad Limited: Healthcare Compliance, Care Delivery and Community Advocacy

Ada Jabaru, the founder and director of Nistad Limited, represents a unique 10KSB success story at the intersection of regulatory compliance, care delivery, and technology management. With over 17 years of experience in regulatory compliance, risk assessment, and financial audit, Jabaru initially built Nistad Limited to provide compliance solutions for financial institutions working with complex investment and asset management software.

However, as a 10KSB UK alumna recognised within the healthcare and medical-related business categories, Jabaru leveraged her expertise in audit and compliance to expand into adult social care and community health systems.

Her clinical and care-related portfolio included directing Flourish Adult Care Limited, alongside her leadership of the Nistad Empowerment Foundation. This foundation supports primary healthcare delivery and educational outreach in underserved communities, with a strong focus on training young people and women from disadvantaged backgrounds in AI and digital skills.

By using the strategic insights gained from the 10KSB programme, Jabaru has become a prominent voice for SME leadership. She has participated in policy panels with senior Goldman Sachs executives at Mansion House, advocating for increased investment in technology education and digital skills to help solve the UK's skills crisis and improve healthcare access.

https://nistadfs.com

AI-Ready Transformation and Digital Telehealth Ecosystems

The convergence of artificial intelligence, real-time analytics, and clinical operations represents the next major growth frontier for healthtech and medtech scale-ups. The 10KSB UK programme has continued to adapt its curriculum to help founders manage this technological transition, focusing on data governance, predictive modelling, and AI-driven clinical workflow automation.

A key example of this focus is Data Inc, which was selected for the 10KSB UK programme in 2026. Data Inc specializes in helping scaling businesses transition toward value-assured, AI-ready operating models.

For modern healthtech and clinical companies, data democratisation and predictive analytics are essential to maintain data reliability, comply with medical regulations, and protect patient information.

By helping founders integrate machine learning and automated quality control, the 10KSB framework enables scaling healthcare companies to deploy predictive tools that improve patient diagnostics and operational agility.

This systemic integration of AI within telehealth ecosystems is also illustrated by Ufonia, a healthtech venture supported by the Oxford Foundry, which is closely integrated with the Saïd Business School 10KSB partnership.

During the pandemic, Ufonia pivoted its AI-telemedicine engine to address the clinical backlogs caused by cancelled procedures.

By automating post-surgery clinical reviews and patient follow-ups via its AI-driven voice platform, Ufonia helped hospitals streamline post-operative workflows, demonstrate the efficacy of automated care, and reduce administrative burdens on frontline healthcare workers.

Overcoming Structural Barriers to Scale in High-Growth Health Sectors

An analysis of the success stories within the 10KSB UK alumni network reveals how specific scaling barriers in the healthcare and life sciences sectors can be systematically addressed through targeted business education:

Distinct Scaling Challenge in Health Sectors	Causal Impact on Business Growth	10KSB Educational & Strategic Solution	Observed Operational Outcome
The Technical Founder Dilemma	Scientific or clinical founders often struggle with the transition from technical experts to strategic CEOs, leading to operational bottlenecks.	Modules on Leadership & Culture focus on strategic delegation, process standardisation, and defining a clear corporate mission.	Clinical and scientific founders successfully transition to strategic business development, enabling larger-scale operations.
The Technical Skills & Talent Crisis	45% of fast-growth SMEs report an inability to access the technical, digital, and data talent needed to sustain their scaling plans.	SME Talent Acquisition Strategy helps founders build internal training systems and structured apprenticeship pathways.	June Medical implemented an apprenticeship model that brought in and trained young talent, supporting global export growth.
Strict Regulatory Compliance & Auditing	Medtech and life sciences products face strict regulatory approval and clinical compliance pathways before market entry.	Modules on Strategic Operations & Metricsprovide frameworks to build audited socio-technical operating models.	Data Inc and Nistad optimized their governance structures, helping de-risk their offerings for institutional partners.
High R&D Capital Requirements	Long clinical development cycles require significant upfront capital before generating sustainable commercial revenues.	Cash & Funding Modulesteach business valuation, pitch readiness, and how to align with patient venture capital.	CatSci secured growth funding from Keensight Capital; Concierge Medical positioned its model for institutional investment.

Navigating the Founder-to-CEO Transition

The transition from a technical founder to a strategic executive is a key tipping point for scaling healthcare businesses. Clinical and scientific founders are trained to focus heavily on scientific accuracy and patient care, which can sometimes lead to a highly centralised management style.

The 10KSB curriculum addresses this by helping founders build a structured management team, delegate day-to-day operations, and focus on long-term corporate positioning.

This shift is clear in the case of CatSci, where the transition from a localised laboratory provider to an international therapeutic development partner was enabled by establishing clear operational roles and institutional governance.

Standardising Operations to Enable Scalable Care

Subscription-based primary care and medical services are structurally limited by the physical capacity of their clinical providers. To scale, these models must standardize their administrative and clinical workflows.

The 10KSB UK programme’s focus on strategic operations helps healthcare businesses utilise technology to automate scheduling, billing, and patient follow-ups.

This process optimisation allowed Concierge Medical to grow its subscriber base by 98% in the months following graduation without needing to add proportional administrative staff, showing how standardising operations can help expand clinical access.

Policy Advocacy, Generation Growth and Future Economic Trajectories

Beyond direct business support, the 10KSB UK programme has become a significant advocate for small business growth, culminating in the launch of "Generation Growth: The Small Business Manifesto" and "The Growth Agenda: Growth Shots" in 2024 and 2025.

These reports, based on detailed surveys of over 550 high-growth 10KSB UK alumni, outline the key policy measures necessary to unlock the full potential of scaling SMEs.

The findings show that while access to capital remains a challenge, with 37% of surveyed small business owners reporting difficulties in obtaining the growth finance they need, the skills shortage is the single largest barrier to scaling.

The Manifesto urges policymakers to prioritise the up-skilling of the UK workforce, ahead of traditional policy focuses like international trade support and business rate reform.

Industry leaders, including ScaleUp Institute CEO Irene Graham OBE and British Business Bank Chair Stephen Welton CBE, have highlighted the importance of these recommendations, emphasising that supporting patient capital and vocational education is vital to unlocking the UK's broader innovation economy.

The success stories of CatSci, June Medical, Principle Healthcare, Concierge Medical, Myonex, and Nistad demonstrate that when scientific and clinical expertise is paired with structured management education, high-growth healthcare companies can scale effectively.

By standardising internal operations, adopting digital and AI-driven workflows, and building structured talent development pipelines, these businesses successfully navigate strict regulatory environments and create high-value employment.

Expanding this educational support across the UK’s broader life sciences, medtech, and healthtech sectors will be key to addressing the nation’s persistent productivity puzzle and driving sustainable, innovation-led economic growth.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech